Skip to main content

Advertisement

Table 4 Cost effectiveness analysis

From: Cost effectiveness of intermittent screening followed by treatment versus intermittent preventive treatment during pregnancy in West Africa: analysis and modelling of results from a non-inferiority trial

Deterministic results (base case)
 DALYs LBW averted −22.64
 DALYs mod/sev anaemia averted −1.63
 DALYs MiP averted −3.56
 Total DALY IPTp-SP 755.1
 Total DALY ISTp-AL 782.93
 Total cost IPTp-SP (US$ 2012)a 9037.84
 Total cost ISTp-AL (US$ 2012)a 13,966.84
 Δ Costs (US$ 2012)a 4929.00
 Δ DALYs −27.83
 ICER (US$/DALY) a 177.10
Probabilistic results
 DALYs LBW averted −23.15 (−128.35 to 80.71)
 DALYs mod/sev anaemia averted −1.63 (−4.35 to 0.94)
 DALYs MiP averted −3.58 (−5.69 to 1.83)
 Total DALY IPTp-SP 753.55 (631.07 to 895.88)
 Total DALY ISTp-AL 781.91 (657.92 to 928.64)
 Total cost IPTp-SP (US$ 2012)a 9006.54 (5610.30 to 13,680.56)
 Total cost ISTp-AL (US$ 2012)a 13,972.79 (10,199.65 to 18,983.86)
 Δ Costs (US$ 2012)a 4966.25 (3703.53 to 6376.83)
 Δ DALYs −28.36 (−134.18 to 75.78)
 Average ICER (US$/DALY) a 175.12
  1. aIncluding the costs from health consequences caused by malaria during pregnancy